Phenotypic Optimization of Urea–Thiophene Carboxamides To Yield Potent, Well Tolerated, and Orally Active Protective Agents against Aminoglycoside-Induced Hearing Loss
摘要:
Hearing loss is a major public health concern with no pharmaceutical intervention for hearing protection or restoration. Using zebrafish neuromast hair cells, a robust model for mammalian auditory and vestibular hair cells, we identified a ureathiophene carboxamide, 1 (ORC-001), as protective against aminoglycoside antibiotic (AGA)-induced hair cell death. The 50% protection (HC50) concentration conferred by 1 is 3.2 mu M with protection against 200 mu M neomycin approaching 100%. Compound 1 was sufficiently safe and drug-like to validate otoprotection in an in vivo rat hearing loss model. We explored the structureactivity relationship (SAR) of this compound series to improve otoprotective potency, improve pharmacokinetic properties and eliminate off-target activity. We present the optimization of 1 to yield 90 (ORC-13661). Compound 90 protects mechanosensory hair cells with HC50 of 120 nM and demonstrates 100% protection in the zebrafish assay and superior physiochemical, pharmacokinetic, and toxicologic properties, as well as complete in vivo protection in rats.
Inhibitors of acyl-CoA:cholesterol acyltransferase. 4. A novel series of urea ACAT inhibitors as potential hypocholesterolemic agents
作者:Bharat K. Trivedi、Ann Holmes、Terri L. Stoeber、C. John Blankley、W. Howard Roark、Joseph A. Picard、Mary K. Shaw、Arnold D. Essenburg、Richard L. Stanfield、Brian R. Krause
DOI:10.1021/jm00074a011
日期:1993.10
We have synthesized a series of N-phenyl-N'-aralkyl and N-phenyl-N'-(1-phenylcycloalkyl)ureas as inhibitors of acyl-CoA:cholesterol acyltransferase (ACAT). This intracellular enzyme is thought to be responsible for the esterification of dietary cholesterol; hence inhibition of this enzyme could reduce diet-induced hypercholesterolemia. For this series of compounds, the in vitro ACAT inhibitory activity
Quinolines useful in treating cardiovascular disease
申请人:Collini D. Michael
公开号:US20050131014A1
公开(公告)日:2005-06-16
This invention provides compounds of formula I
that are useful in the treatment or inhibition of LXR mediated diseases.
本发明提供了式I化合物的用途,它们在治疗或抑制LXR介导的疾病中是有用的。
[EN] ISOINDOLIN-1-ONE COMPOUNDS AS KINASE INHIBITORS<br/>[FR] COMPOSES D'ISOINDOLINE-1-ONE UTILISES EN TANT QU'INHIBITEURS DE KINASE
申请人:ABBOTT LAB
公开号:WO2004108672A1
公开(公告)日:2004-12-16
Compounds having the formula, (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds and compositions containing the compounds.
INHIBITION OF P38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
申请人:Dumas Jacques
公开号:US20120046290A1
公开(公告)日:2012-02-23
This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases, other than cancer and proteolytic enzyme mediated diseases, other than cancer, and pharmaceutical compositions for use in such therapy.
[EN] BORON-CONTAINING SMALL MOLECULES AS ANTIPROTOZOAL AGENTS<br/>[FR] PETITES MOLÉCULES CONTENANT DU BORE EN TANT QU'AGENTS ANTIPROTOZOAIRES
申请人:ANACOR PHARMACEUTICALS INC
公开号:WO2011019612A1
公开(公告)日:2011-02-17
This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. The compounds are of formula (I), wherein Z is S or O; and X is selected from the group consisting of substituted phenyl, substituted or unsubstituted heteroaryl, and unsubstituted cycloalkyl, or a salt thereof.